EBMT Nurses Group launches nurses CML education programme
The Chronic Myeloid Leukaemia Learning Programme, devised by the European Group for Blood and Marrow Transplantation (EBMT) Nurses Group, represents the first specialist Chronic Myeloid Leukaemia (CML) education programme that has been developed in Europe especially for nurses. The programme, which will be launched during the opening ceremony of the annual meeting of the European Group for Blood and Marrow Transplantation (EBMT), to be held in Geneva, Switzerland, 1-4 April, 2012, has been designed to help nurses and other allied health care professionals through the rapidly evolving CML treatment landscape and enable them to deliver optimal care to patients.
>> The programme (PPT slides) is available for download here <<<
CML Horizons 2012: Learn. Share. Grow. 11-13 May 2012, Munich, Germany
The 9th "New Horizons In Treating Cancer Conference", held in Amsterdam in May 2011, was a great success. 137 patient representatives (97 CML, 40 GIST) from 48 countries participated in this meeting. New Horizons has been instrumental in educating patient advocates, building patient groups' capacity, implementing advocacy initiatives. "CML Horizons 2012", held 11-13 May 2012, is now a fully community-run and multi-sponsored conference, run by the CML Advocates Network. An exciting programme has been defined by a global steering committee consisting of CML patient advocates from North America, Latin America, Asia, Europe, Middle East and Africa. Registration has started now - please send us an email if you are a CML patient group that has not received an invitation!
Patient-friendly summary of ELN Guidelines now available in seven languages
Now 64 patient organisations from 51 countries are members of the CML Advocates Network

ASH 2011: Key news on CML from a patients' perspective
Like every year in December, about 21.000 hematologists and health professionals (as well as a small group of patient advocates) convened at the Annual Meeting of the American Society of Hematology (ASH) to hear latest news from research in leukemias, lymphomas and other blood disorders.
We have attended the scientific CML sessions at ASH 2011 and are now summarizing the most important presentations and posters, complemented by a patients' perspective. This report covers key presentations on Nilotinib, Dasatinib, Bosutinib, Ponatinib, DCC-2036, Imatinib-Interferon combination, STOP studies, as well as some studies on CML and diabetes or fatigue.
(Translations: English - Russian - Hebrew - German - French - Macedonian)
ELN Recommendations - Patient-friendly summary (2009 version, outdated)
This is outdated!Please note this is the patient-friendly summary of the 2009 version of the ELN CML Treatment Recommendation. This version is outdated and has been replaced by our summary of the European LeukemiaNET's CML Treatment Recommendations of 2013. You find the most up to date summary here: http://www.cmladvocates.net/cmlsummary We are keeping these recommendations just as a reference, but please use the newer summary instrad. |
To improve the information available to patients, an international CML workgroup of patient organisations and experts have developed a patient-friendly summary of recommendations for CML management. The original recommendations for physicians were published by CML experts on behalf of the European LeukemiaNet (ELN) in the Journal of Clinical Oncology in 2009.
While treatment guidelines and recommendations are recognised as being the standard of care by haematologists, they can be difficult for patients to understand. Thanks to a great community effort, the summary is now available in nine languages: English, French, Spanish, German, Italian, Macedonian, Polish, Serbian and Hungarian! Select the language of your choice!